Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer

NCT07469306 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

130

Enrollment

OTHER_GOV

Sponsor class

Conditions

Locally Advanced Rectal Cancer

Interventions

RADIATION: Modified Short-course radiotherapy
RADIATION: Long-course radiotherapy
DRUG: Oxaliplatin
DRUG: Capecitabine
DRUG: Tislelizumab
DRUG: Capecitabine
DRUG: Tislelizumab

Sponsor

Fujian Cancer Hospital